Market Overview

UPDATE: Cantor Fitzgerald Upgrades Cubist Pharmaceuticals Following Data on New Drug

Related CBST
UPDATE: Credit Suisse Downgrades Cubist Pharmaceuticals On Execution Risk To Global Expansion Of Hospital Franchise
Wedbush Initiates Coverage On Cubist Pharmaceuticals
Is This Superbug Drug Company Right for Your Portfolio? (Fox Business)

In a report published on Tuesday, Cantor Fitzgerald analyst Irina Rivkind upgraded the rating on Cubist Pharmaceuticals (NASDAQ: CBST) from Sell to Hold and raised the price target from $40 to $49.

In the report, Cantor Fitzgerald commented that, "The next big catalyst is in 2H:13 upon the CXA-201 Phase III data release. We actually see some modest risk around the results given that Phase II data in cUTI were slightly numerically weaker than ceftazidime, and Phase II data in cIAI showed a similar trend versus meropenem. Cubist needs to generate positive data in both trials in not only the primary, but also the secondary endpoints to be able to assure attractive pharmacoeconomics and pricing in the U.S. and E.U. markets. While the stock should rally on any positive results, we do see more downside risk around this event given the positive expectations around the data and the critical nature of data quality."

Cubist Pharmaceuticals closed on Monday at $53.48

Latest Ratings for CBST

DateFirmActionFromTo
Nov 2014Credit SuisseDowngradesOutperformNeutral
Nov 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Nov 2014WedbushInitiates Coverage onNeutral

View More Analyst Ratings for CBST
View the Latest Analyst Ratings

Posted-In: Cantor Fitzgerald Irina RivkindAnalyst Color Upgrades Analyst Ratings

 

Related Articles (CBST)

Around the Web, We're Loving...

Get Benzinga's Newsletters